Adverse events after Pfizer’s Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States.
-
アブストラクト BACKGROUND:In September 2023, the Advisory Committee on Immunization Practices recommended Pfizer's Respiratory Syncytial Virus (RSV) vaccine (Abrysvo (R)) for pregnant women at 32-36 weeks' gestation using seasonal administration to prevent RSV-associated lower respiratory tract disease (LRTD) in infants aged <6 months.METHODS:We searched and analyzed reports of adverse events (AEs) after administration of Pfizer's RSV Vaccine in pregnant women submitted to the U.S. Vaccine Adverse Event Reporting System (VAERS) for the 2024-2025 RSV season. Clinicians reviewed reports and available medical records.RESULTS:VAERS received 131 reports of pregnant women who received the Pfizer RSV vaccines. Injection site and systemic reactions were described in 46 (35%) reports. The most reported pregnancy-specific outcomes were preterm birth (n = 15, 11%) and hypertensive disorders of pregnancy (HDP) (n = 9, 7%).CONCLUSIONS:During the second U.S. RSV season in which the Pfizer RSV vaccine was recommended for use during pregnancy, the types of AEs reported were consistent with prelicensure studies.ジャーナル名 Vaccine Pubmed追加日 2026/4/5 投稿者 Moro, Pedro L; Romanson, Brittney; Marquez, Paige; Zhang, Bicheng; Zauche, Lauren Head; Strid, Penelope; Stroud, Erin 組織名 Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for;Disease Control and Prevention (CDC), Atlanta, GA, United States. Electronic;address: psm9@cdc.gov.;Disease Control and Prevention (CDC), Atlanta, GA, United States; Institute of;Health Policy, Management and Evaluation, University of Toronto, 155 College;Street, Suite 425, Toronto, ON, M5T 3M6, Canada.;Disease Control and Prevention (CDC), Atlanta, GA, United States. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/41934687/ -
お問合わせ
検索
メルマガ登録
